Table 6.
Factors affecting AR-V7 positivity on univariable analysis.
| □ | □ | Celsee AR–V7 Positive | Celsee AR-V7 Negative | p |
|---|---|---|---|---|
| Age (SD) | 74.8 (10.8) | 77.1 (8.1) | 0.558 | |
| Gleason score, n (%) | 7 or fewer | 1 (2.4) | 7 (17.1) | |
| 8 or more | 8 (19.5) | 25 (61.0) | 0.659 | |
| PSA ng/mL (SD) | 529.8 (661.5) | 91.7 (167.3 | 0.041 | |
| initial PSA ng/mL (SD) | 3188.1 (4259.2) | 945.5 (2239.9) | 0.161 | |
| LDH U/L (SD) | 340.2 (272.5) | 237.6 (135.2) | 0.302 | |
| ALP U/L (SD) | 1128.4 (1319.5) | 408.3 (448.5) | 0.143 | |
| Hb g/dl (SD) | 11.0 (1.7) | 11.6 (1.6) | 0.389 | |
| Alb g/dl (SD) | 3.5 (0.7) | 3.7 (0.5) | 0.331 | |
| PS, n (%) | 1 or fewer | 5 (12.2) | 25 (60.9) | |
| 2 or more | 4 (9.8) | 7 (17.1) | 0.217 | |
| Metastasis, n (%) | Yes | 9 (22.0) | 29 (70.7) | |
| None | 0 (0) | 3 (7.3) | 1 | |
| Visceral metastasis, n (%) | Yes | 2 (4.9) | 4 (9.8) | |
| None | 7 (17.1) | 28 (68.2) | 0.597 | |
| Lymph node metastasis, n (%) | Yes | 5 (12.2) | 10 (24.4) | |
| None | 4 (9.8) | 22 (53.6) | 0.248 | |
| Bone metastasis, n (%) | Less EOD2 | 3 (7.3) | 27 (65.9) | |
| More EOD3 | 6 (14.6) | 5 (12.2) | 0.006 | |
| Usage history of Abi and/or Enz, n (%) | Yes | 8 (19.5) | 22 (53.7) | |
| None | 1 (2.4) | 10 (24.4) | 0.401 | |
| Usage history of DTX and/or CBZ, n (%) | Yes | 5 (12.2) | 10 (24.4) | |
| None | 4 (9.8) | 22 (53.6) | 0.248 | |
| Current treatment, n (%) | Abi, enz | 2 (4.9) | 17 (41.4) | |
| DTX, CBZ | 4 (9.8) | 8 (19.5) | ||
| Vintage hormone | 2 (4.9) | 7 (17.1) | ||
| Radium223 | 1 (2.4) | 0 (0.0) | 0.142 | |
| Effectiveness of current treatment, n (%) | Stable or response disease | 3 (7.7) | 20 (51.3) | |
| Progression disease | 6 (15.4) | 10 (25.6) | 0.075 | |
| Time to CRPC Month (SD) | 11.2 (10.9) | 32.5 (31.8) | 0.069 | |
| Time from CRPC Month (SD) | 27.7 (13.7) | 27.3 (19.7) | 0.956 | |
| Treatment Line (SD) | □ | 2.8 (1.0) | 2.8 (1.0) | 0.993 |
PSA: Prostate-specific antigen, PS: performance status, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, Hb: hemoglobin, Alb: albumin, Abi: abiraterone, Enz: enzalutamide, DTX: docetaxel, CBZ: cabazitaxel, CRPC: castration-resistant prostate cancer.